Bausch Health Americas, Inc.

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

204

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 12 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

7 drugs in development

Approved2

Phase 35

Phase 21

Phase 11

Preclinical2

By Therapeutic Area

top 6

Immunology

538%

Dermatology

215%

Ophthalmology

18%

Infectious Disease

18%

Neurology

18%

Psychiatry

18%

R&D Momentum

57/100

Pipeline Velocity

32/100

Trial Completion Rate

87/100

Pipeline Concentration

22/100

Pipeline Freshness

59/100

Strategic Signals

↗Active in Dermatology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 10, 2026

Completed

Satisfaction, Adherence, Effectiveness, and Safety of Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Treatment in Patients With Acne Vulgaris: A Canadian Prospective Phase IV Study (CHARM)

Earlier

Aug 29, 2026TrialA Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing Procedures Using the Next Generation Fraxel® FTX Laser System in Participants With Dyschromia, Cutaneous Lesions, and Periorbital Rhytids

Aug 27, 2026TrialA Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment to Improve Lines and Wrinkles and to Lift and Tighten Lax Tissue in the Neck, Abdomen, Upper Arms, and Face

Aug 25, 2026TrialRE-AHFIRM (RandomizEd Study of Larsucosterol in Alcohol-associated Hepatitis to Confirm saFety and effIcacy of tReatMent)

Aug 14, 2026TrialA Randomized, Open-Label Study to Assess Pharmacokinetics of Xifaxan® 200 mg in Pediatric Subjects 6 to 11 Years of Age With Acute Diarrhea of Suspected Bacterial Etiology, and the Safety and Efficacy of Xifaxan® 200 mg Plus Oral Rehydration Therapy (ORT) Compared to ORT Alone

Jul 30, 2026TrialA 12-Week, Phase 4, Open-Label Study To Assess Safety, Pharmacokinetics, and Treatment Effect of CABTREO (Clindamycin Phosphate 1.2%, Adapalene 0.15%, and Benzoyl Peroxide 3.1%) Topical Gel In Pediatric Participants Ages 9 to 11 Years, 11 Month With Acne Vulgaris

Jul 24, 2026TrialA Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy and Safety of Plecanatide in Children and Adolescents Age 6 to <18 Years of Age With Functional Constipation (FC)

Jun 1, 2026TrialEfficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder

4 more events

Feb 21, 2025FDACardizem — DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

Sep 29, 2023TrialStudy to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

May 18, 2023FDAMiebo — MIEBO

Jan 13, 2023FDAAtivan — ATIVAN

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

36 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Dermatology(2 drugs)

—

Dermatology(2 drugs)

Immunology(5 drugs)

—

Immunology(5 drugs)

Infectious Disease(1 drug)

—

Infectious Disease(1 drug)

Neurology(1 drug)

—

Neurology(1 drug)

Ophthalmology(1 drug)

—

Ophthalmology(1 drug)

Psychiatry(1 drug)

—

Psychiatry(1 drug)

Unknown / Other(2 drugs)

—

Unknown / Other(2 drugs)

Regulatory

Regulatory Timeline

20164 events

FDADec 16

Ativan — ATIVAN

Application NDA017794

FDASep 20

Vasotec — EPANED

Application NDA208686 (NDA)

FDAJul 11

Xiidra — XIIDRA

Application NDA208073 (NDA)

FDAMay 27

Ativan — ATIVAN

Application NDA018140

20175 events

FDANov 2

Vyzulta — VYZULTA

Application NDA207795 (NDA)

FDAOct 6

Kenalog — ZILRETTA

Application NDA208845 (NDA)

FDAApr 27

Ativan — ATIVAN

Application NDA018140

FDAApr 27

Ativan — ATIVAN

Application NDA018140

FDAFeb 15

Siliq — SILIQ

Application BLA761032 (BLA)

20192 events

FDADec 18

Tazorac — ARAZLO

Application NDA211882 (NDA)

FDAMar 12

Tetracaine Hydrochloride — TETRACAINE HYDROCHLORIDE

Application NDA210821 (NDA)

20215 events

FDAOct 28

Cardizem — DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%

Application NDA215252 (NDA)

FDAOct 22

Kenalog — XIPERE

Application NDA211950 (NDA)

FDAAug 27

Ativan — LOREEV XR

Application NDA214826 (NDA)

FDAFeb 5

Ativan — ATIVAN

Application NDA018140

FDAFeb 5

Ativan — ATIVAN

Application NDA017794

20233 events

FDAMay 18

Miebo — MIEBO

Application NDA216675 (NDA)

FDAJan 13

Ativan — ATIVAN

Application NDA017794

FDAJan 13

Ativan — ATIVAN

Application NDA018140

20251 event

FDAFeb 21

Cardizem — DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

Application NDA218038 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)